TMB testing should be routinely done in MSI‐H CRC and where TMB  > 35 mut/MB samples should be screened for NTRK and RET fusions as an enrichment strategy to provide an additional treatment option for NTRK+ and RET+ CRC patients. This evidence concerns the gene RET and colorectal carcinoma.